141 related articles for article (PubMed ID: 6408288)
1. [Diagnosis of amelanotic malignant melanoma by means of the fluorescence method (Falck & Hillarp) and determination of 5-S-cysteinyldopa in the lesions].
Morishima T; Fukada E; Nagashima N
Nihon Hifuka Gakkai Zasshi; 1983 Jan; 93(1):51-4. PubMed ID: 6408288
[No Abstract] [Full Text] [Related]
2. Studies on amelanotic melanoma with the fluorescence method (Falck and Hillarp) and biochemical analysis of 5-S-cysteinyldopa in the tissues.
Morishima T; Tatsumi F; Fukada E; Watanabe M; Nagashima N; Hanawa S
Arch Dermatol Res; 1983; 275(5):329-33. PubMed ID: 6419680
[TBL] [Abstract][Full Text] [Related]
3. [Definitive diagnosis of early malignant melanoma lesions by the quantitative analysis of 5-S-cysteinyldopa in the tissue and touch fluorescence method].
Kanematsu S; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 Jun; 99(7):783-91. PubMed ID: 2511360
[TBL] [Abstract][Full Text] [Related]
4. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
Sameshima T; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
[TBL] [Abstract][Full Text] [Related]
5. [Contents of cysteinyldopa isomers and DOPA in lesions of malignant melanoma (author's transl)].
Morishima T; Saito M; Fujita M; Fukada E; Nagashima N; Hanawa S
Nihon Hifuka Gakkai Zasshi; 1982 Feb; 92(2):157-9. PubMed ID: 6806514
[No Abstract] [Full Text] [Related]
6. Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and it's urinary excretion.
Mojamdar M; Ichihashi M; Mishima Y
J Dermatol; 1979 Dec; 6(6):379-82. PubMed ID: 120380
[No Abstract] [Full Text] [Related]
7. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
[TBL] [Abstract][Full Text] [Related]
8. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
Morishima T; Tatsumi F; Fukada E; Saito M; Fujita M; Nagashima N; Hanawa S
Arch Dermatol Res; 1983; 275(2):76-9. PubMed ID: 6409012
[TBL] [Abstract][Full Text] [Related]
9. 5-S-cysteinyldopa in the urine of melanoma patients.
Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
[TBL] [Abstract][Full Text] [Related]
10. 5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations.
Aubert C; Rosengren E; Rorsman H; Rouge F; Foa C; Lipcey C
Eur J Cancer (1965); 1977 Nov; 13(11):1299-308. PubMed ID: 590287
[No Abstract] [Full Text] [Related]
11. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
Paul E; Graef V; Ruppel R
Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
[TBL] [Abstract][Full Text] [Related]
12. [Comparative studies between excretion of 5-S-cysteinyldopa and indole melanogens in urine].
Beyer C; Fiedler H; Wohlrab W; Wozniak KD
Dermatol Monatsschr; 1986; 172(9):541-4. PubMed ID: 3098590
[No Abstract] [Full Text] [Related]
13. [Vitality evaluation of malignant melanoma metastases following endolymphatic radionuclide therapy using the Falck-Hillarp method].
Paul E; Illig L; Möller W
Hautarzt; 1975 Jun; 26(6):317-20. PubMed ID: 1165195
[TBL] [Abstract][Full Text] [Related]
14. Intracellular distribution of dopa and 5-S-cysteinyldopa in Harding-Passey melanoma.
Agrup G; Falck B; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1977; 57(4):313-5. PubMed ID: 70922
[TBL] [Abstract][Full Text] [Related]
15. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
Ichihasi M; Mojamdar M; Mishima Y
Nihon Hifuka Gakkai Zasshi; 1981 Sep; 91(10):1045-9. PubMed ID: 6798247
[No Abstract] [Full Text] [Related]
16. [Pigmented spindle cell nevus and pigmented Spitz nevus--clinical and histopathological study on pigmented Spitz nevus, and its differentiation from early melanoma by fluorescence method and measurement of 5-S-CD level in the lesion].
Takeuchi M; Morishima T
Nihon Hifuka Gakkai Zasshi; 1990 Oct; 100(11):1153-65. PubMed ID: 2273578
[TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
Agrup G; Agrup P; Andersson T; Falck B; Hansson J-A ; Jacobsson S; Rorsman H; Rosengrem A-M ; Rosengren E
Acta Derm Venereol; 1975; 55(5):337-41. PubMed ID: 52967
[TBL] [Abstract][Full Text] [Related]
18. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
Stewart RM; Miller S; Gunder M
Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
[TBL] [Abstract][Full Text] [Related]
19. [A study on quick diagnosis during surgery of malignant melanoma with the touch-fluorescence method].
Nagashima N; Shibata A; Kanematsu S; Fukada E; Hanawa S; Morishima T
Nihon Hifuka Gakkai Zasshi; 1985 Apr; 95(5):597-602. PubMed ID: 4032824
[No Abstract] [Full Text] [Related]
20. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
Horikoshi T; Ito S
J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]